<DOC>
	<DOCNO>NCT01850316</DOCNO>
	<brief_summary>Respiratory-gated , volumetric-modulated arc therapy use clinical development high dose rate Stereotactic Body Radiotherapy ( SBRT ) inoperable hepatocellular carcinoma ( HCC ) . These treatment enhance local control , progression-free survival potentially overall survival HCC patient . The investigator also examine mechanism tumour microenvironmental response high dose radiation , search potential biomarkers optimize individualize therapy . Pre-treatment follow-up PET/CT image 11C-choline , 18F-fluorodeoxyglucose ( FDG ) CT perfusion examine in-vivo change proliferation , glycolysis , tumour vasculature , respectively , blood sample look immunologic biomarkers tumour response .</brief_summary>
	<brief_title>Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy</brief_title>
	<detailed_description>Radiotherapy consider standard care practice patient inoperable hepatocellular carcinoma despite tumour 's inherent radiosensitivity . The major challenge improve radiation delivery without exceed dose limit surround normal liver . Recent technological advance tumour localization targeting , imaging , treatment planning delivery allow safe delivery radiation tumorcidal effect minimal treatment-related toxicity . This study three specific aim : 1 . To develop , validate , quality test HDR Stereotactic Body Radiotherapy ( SBRT ) Gated RapidArc technique application human liver tumour . And furthermore , test whether HDR SBRT Gated RapidArc efficiently safely deliver large patient population previously ineligible therapy ( HCC patient tumours &gt; 5cm ) . 3 . To determine 11C-choline/18F-FDG CT-PET perfusion CT imaging ( characterize change tumour proliferation , glycolysis , vasculature , respectively ) provide practical non-invasive biomarkers tumour response , local tumour control , normal tissue toxicity . 4 . To determine immunologic study pre- post-treatment blood sample provide biomarkers tumour response , local systemic tumour control , trigger normal tissue toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Age &gt; 18 year old 2 . Multiphase CT scan liver within 8 week radiation plan demonstrating : Liver tumours must &gt; 5 cm No 5 discrete liver tumour may present Normal liver &gt; 700 cc 3 . FDGPET scan within 12 week prior radiation plan 4 . Patients must HCC diagnose either : ) pathological confirmation , ii ) intrahepatic vascular enhancement lesion demonstrate least two image modality , iii ) intrahepatic vascular enhancement lesion demonstrate one imaging modality AFP &gt; 200 set liver cirrhosis chronic hepatitis B without cirrhosis ( EASL consensus guideline ) 5 . Liver HCC must deem unresectable determine experienced liver surgeon , patient must medically inoperable refuse surgery , extrahepatic metastasis must present ( Patients potential resectable tumour deem unresectable base medical inoperability simultaneous extrahepatic metastasis eligible receive SBRT ) . 6 . Patients must discuss multidisciplinary setting opinion regard radiofrequency ablation , various embolotherapies , target biologics consider , eligible . Patients must recover effect previous therapy SBRT . 7 . Eastern Clinical Oncology Group performance status 0,1 2 Karnofsky performance status ≥ 60 8 . Adequate organ function assess follow blood work : Hemoglobin ≥ 90 g/L Absolute neutrophil count ≥ 1.0 bil/L Platelets ≥ 50 bil/L AST ALT exceed 2x upper limit normal 9 . ChildTurcottePugh assessment ( within 8 week treatment date ) : Bilirubin ≤ 3 mg/dL ( &lt; 50 µmol/L ) Albumin 28 g/L INR &lt; 1.7 and/or correctable vitamin K ( unless anticoagulation therapy ) No ascites encephalopathy ChildTurcottePugh score must ≤ 7 ( see Table 1 Section 2.1 ) 10 . BCLC Stage B C ( portal venous invasion liver hilum nodal disease ) 11 . No extrahepatic disease life expectancy &gt; 6 month 12 . No chemotherapy concurrent radiotherapy 13 . Previous treatment ( ) radiofrequency ablation , surgery , TACE , Y90 , percutaneous ethanol injection , chemotherapy exclusion criterion provide recurrence document . 14 . Patient sign studyspecific inform consent form . If patient 's mental status precludes , write informed consent may give patient 's legal representative . A translator provide patient language barrier . 15 . Treatment plan meet acceptable dose constraint Liver Veff ≤ 0.55 1 . Patients active hepatitis , encephalopathy , ascites relate liver failure 2 . Female patient pregnant ( verify blood test patient premenopausal ) . Premenopausal patient may also become pregnant participation study . 3 . Prior external beam radiation upper abdomen 4 . Patients distant metastasis extrahepatic nodal progression ( patient portal venous thrombosis liver hilum nodal involvement remain eligible ) 5 . Patients &lt; 700 cc normal liver . 6 . ChildTurcottePugh score &gt; 7 7 . BCLC Stage A , C ( N1 and/or M1 ) , D 8 . Prior gastric , duodenal , variceal bleed within past 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>